Sökning: WFRF:(Chibuye C) >
Safety, tolerabilit...
Safety, tolerability, and immunogenicity of an oral inactivated ETEC vaccine (ETVAX®) with dmLT adjuvant in healthy adults and children in Zambia: An age descending randomised, placebo-controlled trial
-
Sukwa, N. (författare)
-
Mubanga, C. (författare)
-
Hatyoka, L. M. (författare)
-
visa fler...
-
Chilyabanyama, O. N. (författare)
-
Chibuye, M. (författare)
-
Mundia, S. (författare)
-
Munyinda, M. (författare)
-
Kamuti, E. (författare)
-
Siyambango, M. (författare)
-
Badiozzaman, S. (författare)
-
Bosomprah, S. (författare)
-
Carlin, N. (författare)
-
- Kaim, Joanna, 1977 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för mikrobiologi och immunologi,Institute of Biomedicine, Department of Microbiology and Immunology
-
Sjöstrand, B. (författare)
-
Simuyandi, M. (författare)
-
Chilengi, R. (författare)
-
Svennerholm, A. M. (författare)
-
visa färre...
-
(creator_code:org_t)
- 2023
- 2023
- Engelska.
-
Ingår i: Vaccine. - 0264-410X. ; 41:46, s. 6884-6894
- Relaterad länk:
-
https://gup.ub.gu.se...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Enterotoxigenic Escherichia coli (ETEC) is an important cause of moderate to severe diarrhoea in children for which there is no licensed vaccine. We evaluated ETVAX (R), an oral, inactivated ETEC vaccine containing four E. coli strains over-expressing the major colonization factors CFA/I, CS3, CS5, and CS6, a toxoid (LCTBA) and double mutant heat-labile enterotoxin (dmLT) adjuvant for safety, tolerability, and immunogenicity.Methods: A double-blind, placebo-controlled, age-descending, dose-finding trial was undertaken in 40 adults, 60 children aged 10-23 months, and 146 aged 6-9 months. Adults received one full dose of ETVAX (R) and children received 3 doses of either 1/4 or 1/8 dose. Safety was evaluated as solicited and unsolicited events for 7 days following vaccination. Immunogenicity was assessed by evaluation of plasma IgA antibody responses to CFA/I, CS3, CS5, CS6, and LTB, and IgG responses to LTB.Results: Solicited adverse events were mostly mild or moderate with only 2 severe fever reports which were unrelated to the vaccine. The most common events were abdominal pain in adults (26.7 % in vaccinees vs 20 % in placebos), and fever in children aged 6-9 months (44 % vs 54 %). Dosage, number of vaccinations and decreasing age had no influence on severity or frequency of adverse events. The vaccine induced plasma IgA and IgG responses against LTB in 100 % of the adults and 80-90 % of the children. In the 6-23 months cohort, IgA responses to more than 3 vaccine antigens after 3 doses determined as >= 2-fold rise was significantly higher for 1/4 dose compared to placebo (56.7 % vs 27.2 %, p = 0.01). In the 6-9 months cohort, responses to the 1/4 dose were significantly higher than 1/8 dose after 3 rather than 2 doses.Conclusion: ETVAX (R) was safe, tolerable, and immunogenic in Zambian adults and children. The 1/4 dose induced significantly stronger IgA responses and is recommended for evaluation of protection in children.Clinical trials registration: The trial is registered with the Pan African Clinical Trials Registry (PACTR Ref. 201905764389804) and a description of this clinical trial is available on: https://pactr.samrc.ac.za/Trial Design.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Immunologi inom det medicinska området (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Immunology in the medical area (hsv//eng)
Nyckelord
- ETEC
- Vaccine
- Diarrhoea
- ETVAX (R)
- Safety
- Immunogenicity
- Zambia
- enterotoxigenic-escherichia-coli
- heat-labile enterotoxin
- colonization
- factors
- developing-countries
- immune-responses
- disease
- infants
- burden
- Immunology
- Research & Experimental Medicine
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
-
Vaccine
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- Av författaren/redakt...
-
Sukwa, N.
-
Mubanga, C.
-
Hatyoka, L. M.
-
Chilyabanyama, O ...
-
Chibuye, M.
-
Mundia, S.
-
visa fler...
-
Munyinda, M.
-
Kamuti, E.
-
Siyambango, M.
-
Badiozzaman, S.
-
Bosomprah, S.
-
Carlin, N.
-
Kaim, Joanna, 19 ...
-
Sjöstrand, B.
-
Simuyandi, M.
-
Chilengi, R.
-
Svennerholm, A. ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
-
och Immunologi inom ...
- Artiklar i publikationen
-
Vaccine
- Av lärosätet
-
Göteborgs universitet